MOLECULAR PARTNERS ADS/1 (6ML0) - Net Assets
Based on the latest financial reports, MOLECULAR PARTNERS ADS/1 (6ML0) has net assets worth €58.54 Million EUR (≈ $68.44 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€75.70 Million ≈ $88.50 Million USD) and total liabilities (€17.15 Million ≈ $20.05 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See 6ML0 net asset quality index to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €58.54 Million |
| % of Total Assets | 77.34% |
| Annual Growth Rate | -6.98% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 64.9 |
MOLECULAR PARTNERS ADS/1 - Net Assets Trend (2021–2025)
This chart illustrates how MOLECULAR PARTNERS ADS/1's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see 6ML0 market cap overview.
Annual Net Assets for MOLECULAR PARTNERS ADS/1 (2021–2025)
The table below shows the annual net assets of MOLECULAR PARTNERS ADS/1 from 2021 to 2025. Also explore net asset momentum of MOLECULAR PARTNERS ADS/1 to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €80.33 Million ≈ $93.92 Million |
-43.28% |
| 2024-12-31 | €141.64 Million ≈ $165.59 Million |
-19.72% |
| 2023-12-31 | €176.43 Million ≈ $206.26 Million |
-24.98% |
| 2022-12-31 | €235.17 Million ≈ $274.93 Million |
+119.19% |
| 2021-12-31 | €107.29 Million ≈ $125.43 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to MOLECULAR PARTNERS ADS/1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6080300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €392.09 Million | 488.07% |
| Total Equity | €80.33 Million | 100.00% |
MOLECULAR PARTNERS ADS/1 Competitors by Market Cap
The table below lists competitors of MOLECULAR PARTNERS ADS/1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Harmony Electronics
TWO:8182
|
$133.21 Million |
|
Innate Pharma
NASDAQ:IPHA
|
$133.24 Million |
|
Red Robin Gourmet Burgers Inc
NASDAQ:RRGB
|
$133.27 Million |
|
LEWAG Holding Aktiengesellschaft
F:KGR
|
$133.28 Million |
|
Komelon Corporation
KQ:049430
|
$133.18 Million |
|
American Well Corp
NYSE:AMWL
|
$133.17 Million |
|
Turk Prysmian Kablo ve Sistemleri AS
IS:PRKAB
|
$133.17 Million |
|
Gateway Mining Ltd
AU:GML
|
$133.13 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MOLECULAR PARTNERS ADS/1's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 141,637,000 to 80,334,000, a change of -61,303,000 (-43.3%).
- Net loss of 61,651,000 reduced equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-61.65 Million | -76.74% |
| Other Changes | €348.00K | +0.43% |
| Total Change | €- | -43.28% |
Book Value vs Market Value Analysis
This analysis compares MOLECULAR PARTNERS ADS/1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.65x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.07x to 1.65x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €3.32 | €3.54 | x |
| 2022-12-31 | €6.52 | €3.54 | x |
| 2023-12-31 | €5.37 | €3.54 | x |
| 2024-12-31 | €3.84 | €3.54 | x |
| 2025-12-31 | €2.15 | €3.54 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MOLECULAR PARTNERS ADS/1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -76.74%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.27x
- Recent ROE (-76.74%) is below the historical average (-31.87%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -59.45% | -683.65% | 0.05x | 1.61x | €-74.51 Million |
| 2022 | 50.11% | 62.17% | 0.72x | 1.12x | €94.34 Million |
| 2023 | -35.13% | -880.70% | 0.04x | 1.12x | €-79.63 Million |
| 2024 | -38.16% | -1087.38% | 0.03x | 1.12x | €-68.21 Million |
| 2025 | -76.74% | 0.00% | 0.00x | 1.27x | €-69.68 Million |
Industry Comparison
This section compares MOLECULAR PARTNERS ADS/1's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $723,315,608
- Average return on equity (ROE) among peers: -118.42%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MOLECULAR PARTNERS ADS/1 (6ML0) | €58.54 Million | -59.45% | 0.29x | $133.19 Million |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $4.50 Million | -321.01% | 1.17x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $113.23 Million | -53.64% | 0.85x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $3.94 Million | -301.40% | 1.87x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $115.18 Million | -247.79% | 2.83x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $421.77 Million | -87.98% | 0.40x | $189.29 Million |
| PreveCeutical Medical Inc (18H) | $-6.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $5.50 Billion | 15.15% | 0.13x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $39.63 Million | -145.12% | 5.94x | $825.52 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $-2.33 Million | 0.00% | 0.00x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $1.05 Billion | -42.40% | 0.17x | $1.82 Billion |
About MOLECULAR PARTNERS ADS/1
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the trea… Read more